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Abstract
Background Androgen deprivation therapy (ADT) in men with prostate cancer (PCa) results in adverse effects, including
reduced muscle strength and physical function, potentially compromising daily functioning. We examined whether it was
more efficacious to commence exercise at the onset of ADT rather than later in treatment to counter declines in strength and
physical function.
Methods One-hundred-and-four men with PCa (68.3 ± 7.0 years) initiating ADT were randomised to immediate exercise
(IMX, n= 54) or delayed exercise (DEL, n= 50) for 12 months. IMX comprised 6 months of supervised resistance/aerobic/
impact exercise initiated at the onset of ADT with a 6-month follow-up. DEL comprised 6 months of usual care followed by
6 months of resistance/aerobic/impact exercise. Upper and lower body muscle strength and physical function were assessed
at baseline, 6 and 12 months.
Results There was a significant difference for all strength measures at 6 months favouring IMX (P < 0.001), with net
differences in leg press, seated row and chest press strength of 19.9 kg (95% CI, 12.3–27.5 kg), 5.6 kg (3.8–7.4 kg) and
4.3 kg (2.7–5.8 kg), respectively. From 7 to 12 months, DEL increased in all strength measures (P < 0.001), with no
differences between groups at 12 months. Similarly, physical function improved (P < 0.001) in IMX compared with DEL at
6 months for the 6-m fast walk (−0.2, 95% CI −0.3 to −0.1 s), 400-m walk (−9.7, −14.8 to −4.6 s), stair climb (−0.4, −0.6
to −0.2 s) and chair rise (−1.0, −1.4 to −0.7 s), with no differences between groups by 12 months, except for the 6-m fast
walk (P < 0.001).
Conclusion Exercise either at the onset or after 6 months of ADT preserves/enhances muscle strength and physical function.
However, to avoid initial treatment-related adverse effects on strength and function, exercise therapy should be implemented
with initiation of ADT.
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Introduction
Up to half of prostate cancer (PCa) patients at some stage
following diagnosis will undergo androgen deprivation
therapy (ADT) [1, 2]. Although beneficial as a neoadjuvant
and adjuvant treatment delaying disease progression in
patients with localised and advanced disease, reducing tes-
tosterone to castrate levels negatively impacts the patient’s
well-being, co-morbidity risk and quality of life [3, 4].
These treatment toxicities are well established, impacting
multiple body systems [5], and may be especially detri-
mental in older patients with compromised physical capa-
city and numerous comorbidities.
One adverse effect resulting from severe hypogonadism
is a loss of muscle mass [6, 7], which is accompanied by a
decline in muscle strength and physical function [8–12].
However, we and others have demonstrated that deficits in
muscle strength [13–15] and physical function [14, 15] as a
result of ADT in men with PCa can be reversed following a
period of resistance training or combined resistance and
aerobic training. In these trials, men were on established
ADT regimens with exercise initiated with rehabilitative
intent to counter treatment-related toxicities. Nevertheless, a
more opportune time to intervene may be when ADT is
initiated in order to prevent these treatment-related adverse
effects from occurring in the first place. As a result, we
previously undertook a short-term 3-month exercise trial in
men commencing hormone suppression, and were able to
prevent declines in muscle strength and function [16]. In
the trial [16], men were randomised to supervised twice-
weekly moderate-to-high-intensity aerobic and resistance
training, which was undertaken in an exercise clinic or to
usual care. There were significant net differences between
groups at 3 months for upper and lower body muscle
strength, as well as for repeated chair rise test and 400-m
walk, with improved strength and performance in the
exercise, and poorer strength and performance in the usual
care group.
In this report, we extend the findings from our previous
work [14–16], and address whether it is more efficacious to
prevent ADT-related declines in strength and function from
the outset rather than undertaking exercise to rehabilitate the
patient following their development. In this 12-month ran-
domised trial, men either concurrently initiated exercise and
ADT for 6 months (with no supervised exercise in the
following 6 months) or delayed undertaking exercise until
after 6 months of ADT treatment. We hypothesised that
exercise concurrently initiated with ADT would prevent
deficits in muscle strength and physical function from
occurring; however, by 12 months there would be no dif-
ference compared with the delay group where exercise
was commenced with rehabilitative intent. No difference
between groups at 12 months was based on anticipated
improvements in the delay group, with partial reversal of
gains exhibited in the group that undertook immediate
exercise (IMX) [17].
Materials and methods
Patients
Two-hundred-and-nineteen PCa patients were referred by
their treating radiation oncologist/urologist and screened for
participation from August 2013 to April 2015 in Perth,
Western Australia, as previously reported [18]. Inclusion
criteria included commencing ADT and intending to remain
on it for at least the next 6 months, no structured aerobic or
resistance exercise in the past 3 months and able to walk
400 m. Exclusion criteria included prior ADT, established
metastatic disease, established osteoporosis, medications
known to affect bone metabolism, acute illness or any
musculoskeletal, cardiovascular or neurological disorder
that could inhibit or put them at risk from exercising as
determined by their physician. Following screening, 115
patients were excluded mainly due to already-commenced
ADT (n= 29), too far to travel (n= 19), declined to parti-
cipate (n= 17), health issues (n= 13), no time for training
(n= 12), going on holidays (n= 8) and unwilling to be
randomised (n= 6). All the remaining participants obtained
medical clearance from their physician. The study was
approved by the Edith Cowan University Human Research
Ethics Committee, and all participants provided written
informed consent.
Study design
One-hundred-and-four men were randomly assigned by
computer-generated number sequence to IMX or delayed
exercise (DEL), stratified according to age (≤70 and >70
years) and smoking status (yes/no) [18, 19]. Investigators
and research assistants performing the assessments were
blinded to group allocation. The primary endpoint was bone
mineral density, which we have recently reported [18], with
secondary endpoints including muscle strength and physical
function. IMX undertook a programme that combined
resistance+ impact loading+ aerobic exercise for the initial
6 months, with no formal intervention in the second 6-
month period. DEL underwent 6 months of usual care fol-
lowed by the identical exercise programme in the second 6-
month period. Participants received daily supplementation
with calcium (1000 mg/d) and vitamin D3 (800 IU/d)
throughout the study period. Measurements were performed
at baseline, 6 and 12 months.
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Exercise programme
The exercise programme has been previously described in
detail [18, 19]. In brief, the multicomponent exercise
programme was undertaken thrice weekly in several
exercise clinics, and designed to primarily target the
musculoskeletal system consisting of resistance exercise
and impact-loading activities, as well as aerobic-based
activity for cardio-metabolic health. It was structured such
that aerobic and resistance exercise was alternated weekly
so that two resistance/impact loading and one aerobic/
impact-loading session was performed for 1 week with the
reverse performed the following week. Resistance training
consisted of upper and lower body exercises that targeted
the major muscle groups, and included leg press, leg
extension, leg curl, chest press, seated row, lat pulldown
and biceps curl, at an intensity of 6–12 RM (the maximal
weight lifted 6–12 times) for 2–4 sets per exercise. Impact
loading consisted of a series of bounding, hopping,
skipping, leaping and drop-jumping activities, with the
volume and intensity progressively increased over the 6-
month training period. The aerobic-based component
consisted of walking/jogging on a treadmill, and cycling
or rowing on a stationary ergometer at an intensity of
60–85% estimated maximum heart rate for 25–40 min,
with heart rate monitored by using chest straps and heart
rate watches (Polar Electra Oy, Finland). Sessions were
~60 min in duration, undertaken in small groups and
supervised by an exercise physiologist. Each session
commenced with a warm-up comprising aerobic activities
and concluded with stretching activities. To further load
the skeleton, participants were encouraged to undertake
twice-weekly home-based training consisting of a mod-
ified version of the impact-loading programme, and
aerobic activities such as walking or cycling.
Muscle strength and physical function
Dynamic concentric muscle strength for the chest press,
leg press and seated row exercises was assessed using the
one-repetition maximum method [20]. Physical function
was determined by a battery of performance tests
[14, 15, 21], and included the usual and fast 6-m walk (as
measures of gait speed), 6-m backwards tandem walk
(dynamic balance), 400-m walk (cardiorespiratory fitness
and walking endurance), stair climb (lower body power)
and repeated chair rise test (lower body function). Tests
were performed in triplicate, except for the 400-m walk
that was performed once, with the fastest time used in the
analyses. Participants completed a familiarisation session
to become accustomed to each of the test protocols prior
to the first testing session.
Other measures
Height and weight were assessed using a stadiometer and
electronic scales, respectively, with body mass index (BMI,
kg/m2) calculated. Body fat percentage was determined by
dual-energy X-ray absorptiometry (Hologic Discovery A,
Waltham, MA, USA). Physical activity was assessed by the
Leisure Score Index of the Godin Leisure-Time Exercise
Questionnaire [22]. Testosterone and prostate-specific
antigen (PSA) were measured commercially by an accre-
dited Australian National Association of Testing Authorities
laboratory (Pathwest Diagnostics, Perth, WA).
Statistical analyses
Data were analysed using IBM SPSS Version 24 (IBM
Corp., Armonk, NY, USA). Normality of the distribution
was assessed using the Kolmogorov–Smirnov test.
Between-group differences in baseline characteristics were
assessed using independent t tests or the Mann–Whitney U
test, as appropriate, for continuous data, and χ2 for cate-
gorical data. Changes in muscle strength and physical
function were assessed using analysis of covariance (base-
line value as a covariate), with change from 0 to 6 months, 7
to 12 months and 0 to 12 months assessed. Data that were
not normally distributed were log transformed (ln) for
analysis. Intention-to-treat was utilised for analyses using
maximum likelihood imputation of missing values (expec-
tation maximisation). Baseline to 12-month comparisons for
strength and function within groups were assessed using
either paired t tests or the Wilcoxon signed-rank test.
Freidman’s ANOVA with Bonferroni-adjusted Wilcoxon
signed-rank test as the follow-up test was used for other
measures with three time points. Tests were two-tailed, and
to adjust for multiple comparisons, statistical significance
was set at an α level of 0.01. Values are reported as the
mean ± SD or median and interquartile range (IQR).
Results
There was no difference in any demographic or clinical
characteristics between groups at baseline (Table 1). Men
were aged 48–84 years and 6.0 ± 2.0 days since the first
treatment injection (Lucrin or Zoladex). Six men in IMX
discontinued the intervention and 13 men in DEL withdrew
during the initial 6 months with an additional participant
from IMX lost to follow-up and 5 from DEL withdrawing
by 12 months [18]. The main reasons for discontinuing
exercise were unrelated injury (n= 2), health issues (n= 2)
and no longer interested (n= 2), and for those lost to
follow-up were health issues (n= 6), wanted to begin
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exercise (n= 3) and no longer interested (n= 2). As pre-
viously reported [18], treatment alterations occurred such
that during the initial 6 months, 10 men in IMX and 5 in
DEL ceased ADT, and 40 men in IMX and 30 men in DEL
commenced radiotherapy that continued into the initial
portion of the second 6-month period for 11 men in IMX
and 8 in DEL. For months 7–12, an additional 19 men from
IMX and 17 from DEL ceased ADT, while 1 participant in
IMX recommenced ADT, with 4 additional men from IMX
and 2 from DEL initiating radiotherapy. In addition, 8 men
in IMX and 4 in DEL who previously had external beam
radiation underwent brachytherapy during the second
6-month period. Patients in IMX attended 79% of the
scheduled exercise sessions, and those in DEL attended
69% of scheduled sessions. In regard to the home-based
programme, IMX completed 29 ± 17 impact and 31 ± 16
aerobic sessions, while DEL completed 22 ± 20 impact and
33 ± 13 aerobic sessions, with no difference between groups
for either component (impact, P= 0.233; aerobic, P=
0.754). More detailed explanation of retention and adher-
ence is provided in our previous paper [18]. There were no
major adverse events related to the training programme.
Muscle strength
There were no differences between groups at baseline for
any muscle strength measure (P= 0.379–0.825). Following
initiation of ADT and exercise, strength improved (P <
0.001) for the chest press, leg press and seated row
Table 1 Participant characteristics.
IMX (n= 54) DEL (n= 50) P value
Age, year 69.0 ± 6.3 67.5 ± 7.7 0.266
Height, cm 173.4 ± 7.1 172.7 ± 6.2 0.602
Weight, kg 82.9 ± 16.4 84.6 ± 12.9 0.551
BMI, kg/m2 27.5 ± 4.4 28.3 ± 3.9 0.282
Body fat (%) 29.0 ± 5.1 30.4 ± 5.2 0.159
Married, N (%) 42 (77.8) 41 (82.0) 0.914
Currently employed, N (%) 13 (24.1) 17 (34.0) 0.264
Tertiary education, N (%) 13 (24.1) 11 (22.0) 0.802
Current smoker, N (%) 5 (9.3) 3 (6.0) 0.533
Number of medications 3.0 (2.0–5.0) 3.0 (2.0–5.3) 0.715
Godin LSI, median (IQR) 10.0
(0.0–24.5)
10.0
(0.0–27.0)
0.872
Gleason score 7.6 ± 1.0 7.6 ± 0.8 0.829
PSA, ng/mL median (IQR) 3.4 (0.7–6.4) 3.9 (0.2–10.0) 0.599
Testosterone, nmol/L
median (IQR)
8.0 (2.0–16.0) 4.6 (1.9–15.8) 0.413
Time since ADT
injection (days)
6.4 ± 2.1 5.7 ± 1.9 0.110
Prostatectomy, N (%) 15 (27.7) 17 (34.0) 0.532
Radiation, N (%) 4 (7.4) 3 (6.0) 0.775
Number of comorbiditiesa 1.0 (1.0–2.0) 1.5 (1.0–2.0) 0.646
Values are the mean ± SD unless stated otherwise.
IMX immediate exercise, DEL delayed exercise, BMI body mass index,
LSI Leisure Score Index with a moderate-to-strenuous LSI ≥ 24 classed
as active and ≤23 classed as insufficiently active, PSA prostate-specific
antigen, ADT androgen deprivation therapy, IQR interquartile range.
aCardiovascular disease, hypertension, diabetes and dyslipidaemia.
Table 2 Muscle strength at baseline, 6 and 12 months.
Baseline 6 months 12 months 0–6 monthsd 7–12 monthse 0–12 monthsf
Adj. Diff. P valuec Adj. Diff. P valuec Adj. Diff. P valuec
Chest press (kg)a
IMX 43.4 ± 12.8 44.7 ± 12.5 46.3 ± 12.1 4.3 (2.7, 5.8) <0.001 −5.2 (−7.1, −3.3) <0.001 −1.5 (−3.9, 1.0) 0.160
DEL 46.0 ± 16.3 42.8 ± 14.7 49.8 ± 13.9
Leg press (kg)a
IMX 119.0 ± 49.9 138.8 ± 51.6 142.8 ± 55.4 19.9 (12.3, 27.5) <0.001 −18.7 (−25.0, −12.5) <0.001 1.7 (−8.0, 11.4) 0.937
DEL 119.6 ± 48.4 119.5 ± 48.0 141.7 ± 51.4
Seated row (kg)b
IMX 73.9 ± 16.1 76.4 ± 15.2 77.3 ± 15.8 5.6 (3.8, 7.4) <0.001 −5.9 (−7.7, −4.1) <0.001 0.0 (−2.3, 2.4) 0.971
DEL 75.6 ± 16.6 72.5 ± 14.2 78.8 ± 16.7
Values are the mean ± SD.
IMX immediate exercise, DEL delayed exercise, Adj. Diff. ANCOVA adjusted mean difference and 95% CI.
aIMX n= 53, DEL n= 48.
bIMX n= 53, DEL n= 49.
cP value based on log transformed data for chest press and leg press.
d6 months adjusted for baseline value.
e12 months adjusted for 6-month value.
f12 months adjusted for baseline value.
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exercises in IMX compared with DEL with adjusted dif-
ferences of 4.3 kg, 19.9 kg, and 5.6 kg, respectively
(Table 2). During this period, the strength declines were
modest in DEL being 7% for the chest press and 4% for the
seated row. Following exercise in DEL from 7 to
12 months, muscle strength increased in all three exercises
(P < 0.001) with comparable gains to that observed for IMX
during the initial 6 months such that by 12 months there
were no differences between groups (P= 0.160–0.971). At
12 months, upper and lower body strength was significantly
greater (P < 0.01) than at baseline for IMX and DEL.
Physical function
At baseline, there were no differences between IMX and
DEL (P= 0.222–0.920). Following 6 months exercise in
IMX, performance improved compared with DEL (P <
0.001) for the fast 6-m walk, 400-m walk, stair climb, and
repeated chair rise test (Table 3). Detrimental changes in
performance for DEL during the non-exercise period were
modest at 2–7% for the walking tests and stair climb. Fol-
lowing exercise in DEL from 7 to 12 months, performance
improved (P ≤ 0.001) for the 400-m walk, stair climb, and
repeated chair rise with no difference between IMX and
DEL at 12 months for any measure except for the 6-m fast
walk where the modest adjusted difference of −0.2 s
remained significant (P < 0.001) favouring IMX. Compared
with baseline, at 12 months, repeated chair rise was sig-
nificantly faster (P < 0.001) in both IMX and DEL, while
stair climb time (P= 0.007) and 6-m fast-walk time (P=
0.005) were also improved in IMX. In contrast, usual 6-m
walk time was slower (P < 0.01) in both IMX and DEL, as
was 6-m fast-walk time (P < 0.001) in DEL.
Other measures
PSA levels were reduced (P < 0.001) following administration
of ADT in IMX and DEL at 6 [IMX, median (IQR) 0.1
(0.0–0.2); DEL 0.1 (0.0–0.4) ng/ml] and 12 months [IMX, 0.0
(0.0–0.1); DEL 0.1 (0.0–0.2) ng/ml]. Similarly, testosterone
was reduced at 6 months (P < 0.001) [IMX, 0.5 (0.5–0.7);
DEL 0.5 (0.4–0.7) nmol/L] but not 12 months due to treat-
ment alterations [IMX, 6.4 (0.6–11.8); DEL 7.1 (1.1–13.5)
nmol/L]. As expected, physical activity levels increased in
Table 3 Physical function at baseline, 6 and 12 months.
Baseline 6 months 12 months 0–6 monthsc 7–12 monthsd 0–12 monthse
Adj. Diff. P valueb Adj. Diff. P valueb Adj. Diff. P valueb
6-m usual walk (s)
IMX 4.2 ± 0.6 4.4 ± 0.6 4.3 ± 0.6 −0.03 (−0.2, 0.1) 0.409 −0.1 (−0.2, 0.1) 0.348 −0.1 (−0.2, 0.1) 0.121
DEL 4.2 ± 0.7 4.4 ± 0.5 4.5 ± 0.6
6-m fast walk (s)
IMX 3.2 ± 0.5 3.1 ± 0.5 3.1 ± 0.5 −0.2 (−0.3, −0.1) <0.001 0.0 (−0.1, 0.1) 0.789 −0.2 (−0.3, −0.1) <0.001
DEL 3.2 ± 0.6 3.3 ± 0.6 3.3 ± 0.6
6-m backwards tandem walk (s)a
IMX 13.2 ± 4.1 13.7 ± 4.7 12.9 ± 3.9 −0.6 (−2.2, 1.1) 0.527 −0.4 (−1.7, 0.9) 0.406 −0.6 (−1.9, 0.7) 0.643
DEL 13.9 ± 5.3 14.9 ± 7.2 14.1 ± 6.1
400-m walk (s)
IMX 246.8 ± 36.1 241.9 ± 37.8 245.8 ± 40.4 −9.7 (−14.8, −4.6) <0.001 9.9 (5.0, 14.8) <0.001 0.5 (−5.5, 6.4) 0.981
DEL 258.7 ± 53.8 263.7 ± 56.9 257.7 ± 57.5
Stair climb (s)
IMX 4.8 ± 1.3 4.6 ± 1.3 4.7 ± 1.3 −0.4 (−0.6, −0.2) <0.001 0.4 (0.2, 0.6) <0.001 0.0 (−0.1, 0.2) 0.712
DEL 5.0 ± 1.5 5.2 ± 1.6 4.8 ± 1.4
Repeated chair rise (s)a
IMX 10.7 ± 2.2 9.9 ± 1.8 9.8 ± 1.7 −1.0 (−1.4, −0.7) <0.001 0.6 (0.2, 0.9) 0.001 −0.2 (−0.6, 0.1) 0.116
DEL 11.4 ± 2.9 11.4 ± 2.5 10.1 ± 2.1
Values are the mean ± SD.
IMX immediate exercise, DEL delayed exercise, Adj. Diff. ANCOVA adjusted mean difference and 95% CI.
aIMX n= 54, DEL n= 49.
bP value based on log transformed data except for 6-m usual walk at 7–12 months.
c6 months adjusted for baseline value.
d12 months adjusted for 6-month value.
e12 months adjusted for baseline value.
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IMX at 6 and 12 months (P= 0.001), and in DEL over the
year-long trial (P= 0.033), although the source of the dif-
ferences was not detected in follow-up testing.
Discussion
This year-long trial comparing immediate vs. DEL in men
with PCa commencing ADT produced three important find-
ings: (1) commencing targeted exercise at the onset of ADT
not only preserved but improved muscle strength and physical
function in the initial treatment period; (2) losses that did
occur in strength and function in DEL during the initial
6 months were recouped with further gains derived following
training; (3) by 12 months, muscle strength and physical
function were comparable in IMX and DEL. These results
indicate that initiating exercise either at the onset of ADT or
after 6 months of treatment is effective, both for not only
preserving but also enhancing muscle strength and physical
function. However, to avoid any treatment-related declines in
muscle strength and function following the initiation of ADT,
exercise should be commenced at the onset of treatment.
There were significant differences between groups in
both upper and lower body strength at 6 months, such that
gains were observed in IMX with modest losses in upper
body strength in DEL and lower body strength remaining
unchanged. Moreover, the magnitude of the adjusted dif-
ference in all three strength measures was similar to our
previous 3-month trial in men initiating ADT [16]. Of
interest is that in our previous trial, there was also little
change in leg press strength for men initiating ADT and
undergoing usual care, whereas chest press and seated row
strength declines of 6 and 3% were similar to the declines in
DEL of 7% and 4%, respectively. In addition, in a previous
cross-sectional study we undertook in men on ADT we
observed that although upper body strength was adversely
affected, the results were mixed for lower body strength
with leg extension but not leg press strength reduced
compared with healthy controls [11].
It may well be that upper body strength is more sus-
ceptible to the adverse effects of ADT-induced hypogo-
nadism than lower body musculature, which is more subject
to higher daily usage and intensity via walking, climbing
stairs or rising from a seated position, and leisure-based
activities such as jogging or cycling. In any event, declines
in strength that occurred in DEL during the initial 6 months
were recouped with further gains occurring such that by
12 months there were no differences between groups.
Moreover, upper and lower body strength at 12 months was
significantly greater than that at baseline in both groups,
which would provide a greater reserve capacity for the
performance of daily activities, helping to prolong inde-
pendent living and potentially survival [23–26].
Also of interest is that the muscle strength gains in IMX
at 6 months were not only preserved at 12 months, but there
were also additional modest gains, although these were not
statistically significant. This may be due to activity under-
taken by the men during this non-supervised period,
although this was not monitored as we were interested in
determining if any residual effect would have occurred from
the supervised period without additional tools or strategies
regarding exercise participation.
As with muscle strength, exercise not only prevented
declines but also enhanced physical function in most mea-
sures in IMX relative to DEL at 6 months, with no differ-
ence following training in DEL at 12 months, except for the
6-m fast walk that continued to favour IMX. Again, adverse
changes in DEL were modest with initiation of ADT and
similar to our previous 3-month trial [16]. In contrast, the
differences we observed in our cross-sectional report [11]
for the same performance battery in men on established
ADT compared with healthy age-matched men were larger
ranging from 5 to 20%. The short-term duration of ADT
may partially account for the modest declines in function
observed in DEL. In a cross-sectional study by Clay et al.
[9], physical function was lower in men on long-term ADT
(≥6 months) but not short-term ADT. In a similar fashion,
Levy et al. [27] reported longer chair rise time in men on
chronic ADT compared with men on acute ADT and non-
ADT men at baseline of a 2-year study, and that men in both
ADT groups had greater declines in 4-m walking velocity
over the follow-up period compared with non-ADT men.
Preserving physical function is important as it may
enhance patient outcomes and survival. For instance, in the
Health ABC Study of older community-dwelling adults,
poorer 400-m walk performance, which is related directly to
maximal oxygen consumption [28], was associated with
mortality, cardiovascular disease, mobility limitation and
disability [29], while Cesari et al. [30] reported that poor
physical performance was predictive of lower extremity
limitation, hospitalization, and death. Moreover, in a recent
systematic review in cancer patients, poorer physical per-
formance was associated with treatment-related complica-
tions and poorer survival [31]. Consequently, the
undertaking of exercise, preferably that is targeted and
supervised [32], should be recommended to patients com-
mencing ADT, especially those with comorbidities and
poorer strength and function who may have little reserve
capacity for the performance of daily functioning.
Due to changes in treatment, testosterone was actually
higher at 12 months compared with 6 months in both groups.
Whether this contributed to performance improvements
through anabolic facilitation of training adaptation for the DEL
group can only be speculated. However, this may account in
part for the total reversal of the ADT-driven performance
decline of this group being equivalent to IMX at 12 months.
462 R. U. Newton et al.
There are several strengths of this study. First, we
compared exercise with preventative vs. rehabilitative
intent, which is the customary way that exercise is admi-
nistered to this patient group, to counter ADT-related
adverse effects on strength and function. Second, we
included both upper and lower body dynamic muscle
strength, as well as several objective performance measures
capturing different components of physical function. Third,
patients undertook a supervised multicomponent program
that was designed to counter a range of musculoskeletal and
cardio-metabolic treatment-related toxicities. However,
there are limitations in that a few patients in both groups
also underwent radiotherapy during the trial, a result largely
of being referred by radiation oncologists. In addition,
several men in both groups had their treatment altered
during the trial, which reflects the nature of treatment
changes based on patient responses, disease progression,
and developments in clinical practice. It needs to be noted
that a relatively high attrition of 36% occurred in DEL,
although those who dropped out were not distinguished
from those who completed the trial for any baseline char-
acteristics, including muscle strength and physical function.
The patients in this study may not represent all men with
PCa undergoing ADT as they have agreed to participate in
an exercise intervention.
In conclusion, implementing exercise in PCa patients
initiating ADT not only preserves but enhances muscle
strength and physical function, despite their compromised
hormonal status. Similarly, exercise commenced after the
initial period of ADT and undertaken with rehabilitative intent
is beneficial for the PCa patient in recouping losses and
enhancing strength and function. Nevertheless, it would
appear that initiating exercise therapy at the onset of treatment
should be prescribed in order to not only prevent the devel-
opment of any adverse effects, but also to enhance muscle
strength and physical function, and potentially progression of
comorbidities. Future research should be directed to com-
paring more targeted exercise prescription, addressing specific
issues of individual patients resulting from ADT, for example,
muscle loss, fat gain and bone loss, rather than the generic
multimodel programme evaluated in this study.
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